Cargando…

SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy

OBJECTIVES: Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease activity and predicting progression, (ii) designing trials that allow rapid assessment of candidate therapies, and (iii) understanding molecular causes and consequences of the disease. Validated biomarkers of SMA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Dione T., Shi, Jing, Stephen, Laurie, Ballard, Karri L., Dewey, Ruth, Mapes, James, Chung, Brett, McCarthy, Kathleen, Swoboda, Kathryn J., Crawford, Thomas O., Li, Rebecca, Plasterer, Thomas, Joyce, Cynthia, Chung, Wendy K., Kaufmann, Petra, Darras, Basil T., Finkel, Richard S., Sproule, Douglas M., Martens, William B., McDermott, Michael P., De Vivo, Darryl C., Walker, Michael G., Chen, Karen S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615018/ https://www.ncbi.nlm.nih.gov/pubmed/23565191 http://dx.doi.org/10.1371/journal.pone.0060113

Ejemplares similares

Candidate Proteins, Metabolites and Transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
por: Finkel, Richard S., et al.
Publicado: (2012)

Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
por: Crawford, Thomas O., et al.
Publicado: (2012)

Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!
por: Bartlett, Amy, et al.
Publicado: (2018)

Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States
por: Darras, Basil T., et al.
Publicado: (2022)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities
por: Rodriguez-Torres, Rafael S., et al.
Publicado: (2023)

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy
por: Chiriboga, Claudia A., et al.
Publicado: (2016)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function †
por: Dunaway Young, Sally, et al.
Publicado: (2023)

An overview of the Cure SMA membership database: Highlights of key demographic and clinical characteristics of SMA members
por: Belter, Lisa, et al.
Publicado: (2018)

2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
por: Stimpson, Georgia, et al.
Publicado: (2023)

A Method for Combining Thin and Thick Malleable Titanium Mesh in the Repair of Cranial Defects
por: Lau, Darryl, et al.
Publicado: (2015)

Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

A call to introduce newborn screening for spinal muscular atrophy (SMA) in Scotland
por: Gillingwater, Thomas H., et al.
Publicado: (2022)

High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): Retrospective Analysis of the Kids’ Inpatient Database (KID)
por: Cardenas, Jessica, et al.
Publicado: (2018)

SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
por: Kayadjanian, Nathalie, et al.
Publicado: (2013)

Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA Cohort
por: Jones, Cynthia C., et al.
Publicado: (2020)

The clinical spectrum of SMA‐PME and in vitro normalization of its cellular ceramide profile
por: Lee, Michelle M., et al.
Publicado: (2022)

The effectiveness of styrene-maleic acid (SMA) copolymers for solubilisation of integral membrane proteins from SMA-accessible and SMA-resistant membranes
por: Swainsbury, David J.K., et al.
Publicado: (2017)

Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada
por: McMillan, H.J., et al.
Publicado: (2021)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
por: Darras, Basil T., et al.
Publicado: (2019)

SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy
por: Swoboda, Kathryn J., et al.
Publicado: (2010)

Development of an International SMA Bulbar Assessment for Inter-professional Administration
por: Dunaway Young, Sally, et al.
Publicado: (2023)

SMA CARNI-VAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy
por: Kissel, John T., et al.
Publicado: (2011)

Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening
por: Glascock, Jacqueline, et al.
Publicado: (2018)

Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2021)

Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2
por: Glascock, Jacqueline, et al.
Publicado: (2020)

A new deletion allele of sma-4
por: McKillop, Alexandra N, et al.
Publicado: (2018)

Calcium channels SMA
por: Williams, Ruth
Publicado: (2007)

Alambres musculares (SMA) /
por: Hernández Ramírez, Edgar
Publicado: (2001)

Yeo and Darras: Extraneuronal Phenotypes of Spinal Muscular Atrophy
por: Yeo, Crystal Jing Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ogj1qj7nhaqnr5nlfqakoj6tpr